[PDF][PDF] Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF …
S De Vita, L Quartuccio, S Salvin, L Picco… - Clin Exp …, 2014 - clinexprheumatol.org
S De Vita, L Quartuccio, S Salvin, L Picco, CA Scott, M Rupolo, M Fabris
Clin Exp Rheumatol, 2014•clinexprheumatol.orgObjective The overexpression of B-cell activating factor (BAFF) in mucosa-associated
lymphoid tissue (MALT) may decrease the efficacy of rituximab treatment in Sjögren's
syndrome (SS). Anti-CD20 therapy was effective on marginal zone B cells, in the murine
model for human CD20 expression only when preceded by anti-BAFF therapy. The possible
efficacy of a sequential anti-BAFF/anti-CD20 therapy in SS was investigated.
lymphoid tissue (MALT) may decrease the efficacy of rituximab treatment in Sjögren's
syndrome (SS). Anti-CD20 therapy was effective on marginal zone B cells, in the murine
model for human CD20 expression only when preceded by anti-BAFF therapy. The possible
efficacy of a sequential anti-BAFF/anti-CD20 therapy in SS was investigated.
Objective
The overexpression of B-cell activating factor (BAFF) in mucosa-associated lymphoid tissue (MALT) may decrease the efficacy of rituximab treatment in Sjögren’s syndrome (SS). Anti-CD20 therapy was effective on marginal zone B cells, in the murine model for human CD20 expression only when preceded by anti-BAFF therapy. The possible efficacy of a sequential anti-BAFF/anti-CD20 therapy in SS was investigated.
clinexprheumatol.org
